Break it Down: Invion completes six patient dosings in cancer trial

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Tylah Tully breaks down the latest scoop from Invion (ASX:IVX), which has achieved a major milestone in its Phase I/II clinical trial for INV-043.

Invion has completed the dosing of six patients, triggering a review from the Safety Review Committee, and ultimately paving the way for the next stage in the trial for non-melanoma skin cancers.